Cancer stem cells of hepatocellular carcinoma

Kewei Wang; Dianjun Sun

doi:10.18632/oncotarget.24623

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Cancer stem cells of hepatocellular carcinoma

Kewei Wang _ and Dianjun Sun

PDF | HTML | How to cite

Oncotarget. 2018; 9:23306-23314. https://doi.org/10.18632/oncotarget.24623

Metrics: PDF 1852 views | HTML 3577 views | ?

Abstract

Kewei Wang1,2,3,4 and Dianjun Sun2,3,4

1Institute of Cell Biotechnology, China and Russia Medical Research Center, Harbin Medical University, Harbin, China

2Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin, China

3Key Laboratory of Etiology and Epidemiology (23618504), National Health and Family Planning Commission of the People’s Republic of China, Harbin, China

4Harbin Medical University, Harbin, China

Correspondence to:

Kewei Wang, email: [email protected]

Keywords: hepatocellular carcinoma; cancer stem cells; hepatic oval cells; apoptosis; CAR T-cells

Received: June 13, 2017 Accepted: February 12, 2018 Published: May 01, 2018

ABSTRACT

Hepatocellular carcinoma is a malignant tumor arising from hepatocytes. The hepatocellular carcinoma is dictated by a subset of cells with stem cell-like features. These cells are apoptosis-resistant and have particular biomarkers, which serve as seeds in different stages of tumorigenesis including initiation, progression, metastasis, and relapse of hepatocellular carcinoma. Signaling pathways of cancer stem cells are novel targets for the radical intervention of hepatocellular carcinoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24623

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Cancer stem cells of hepatocellular carcinoma

Abstract